oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations
Univ Gothenburg, Dept Infect Dis, Inst Biomed, Gothenburg, Sweden.
Orebro Univ Hosp, Dept Infect Dis, Orebro, Sweden.ORCID iD: 0000-0001-7248-0910
Univ Gothenburg, Dept Infect Dis, Inst Biomed, SE-41346 Gothenburg, Sweden; Karolinska Univ Hosp, Swedish Reference Grp Antiviral Therapy RAV, Stockholm, Sweden.
Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.
Show others and affiliations
2012 (English)In: Scandinavian Journal of Infectious Diseases, ISSN 0036-5548, E-ISSN 1651-1980, Vol. 44, no 7, 502-521 p.Article in journal (Refereed) Published
Abstract [en]

Swedish recommendations for the treatment of hepatitis C virus (HCV) infection were updated at a recent expert meeting. Therapy for acute HCV infection should be initiated if spontaneous resolution does not occur within 12 weeks. The recommended standard-of-care therapy for chronic HCV genotype 1 infection is an HCV protease inhibitor in combination with peginterferon (peg-IFN) and ribavirin. Treatment is strongly recommended in patients with bridging fibrosis and cirrhosis, whereas in patients with less advanced fibrosis, deferring therapy may be preferential in light of likely therapeutic improvements in the near future. Patients with chronic genotype 2/3 infection should generally be treated with peg-IFN and ribavirin for 24 weeks. In patients with a very rapid viral response (i.e. HCV RNA below 1000 IU/ml on day 7), or favourable baseline characteristics and undetectable HCV RNA week 4, treatment can be shortened to 12-16 weeks, provided that no dose reductions are needed.

Place, publisher, year, edition, pages
2012. Vol. 44, no 7, 502-521 p.
Keyword [en]
Hepatitis C virus; guidelines; HCV protease inhibitor; interferon; ribavirin
National Category
Infectious Medicine
Research subject
Infectious Diseases
Identifiers
URN: urn:nbn:se:oru:diva-37599DOI: 10.3109/00365548.2012.669045ISI: 000305466400005PubMedID: 22506634Scopus ID: 2-s2.0-84862519567OAI: oai:DiVA.org:oru-37599DiVA: diva2:753550
Note

Josephson Filip for Swedish Consensus Group

Available from: 2014-10-08 Created: 2014-10-08 Last updated: 2016-12-01Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Duberg, Ann-Sofi
In the same journal
Scandinavian Journal of Infectious Diseases
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 246 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf